Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Ontario
-
Barrie、Ontario、加拿大、L4M 6L2
- Ultranova Skincare
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Signed and dated informed consent to be obtained prior to any trial related procedure, including washout.
- Clinical diagnosis of psoriasis vulgaris involving trunk and/or arms and/or legs with a symmetrical distribution amenable to treatment with a maximum of 50 g/week of topical medication on each side of the body. At Visit 1, there should not be a difference between the right and left side of more than 1 for each of the PASI criteria (redness, thickness and scaliness).
- A minimum PASI score for extent of 2 on each side in at least one body region (i.e. psoriasis affecting at least 10% of left and right arm, and/or 10% of left and right side of the trunk, and/or 10% of left and right leg).
- Disease severity graded mild, moderate, severe or very severe according to the Investigator's global assessment (IGA) of disease severity on each side of the body. The assessment should be the same for both sides of the body.
- Age 18 years or above
- Male subjects, or females of non-childbearing potential (i.e. surgically sterile or at least two years postmenopausal)
- Attending a hospital outpatient clinic or the private practice of a dermatologist
Exclusion Criteria:
- Subjects using systemic treatments with biological therapies with a possible effect on psoriasis vulgaris within 12 weeks prior to randomisation (e.g. alefacept, efalizumab, etanercept, infliximab, adalimumab)
- Systemic treatment with all other therapies, besides biologics, with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 4 weeks prior to randomisation (inhaled or intranasal steroids for asthma or rhinitis may be used)
- PUVA or Grenz ray therapy within 4 weeks prior to randomisation
- UVB therapy within 2 weeks prior to randomisation
- Any topical treatment (except for emollients) of the trunk/limbs (except on flexures) within 2 weeks prior to randomisation
- Topical treatment for other relevant skin disorders on the face and flexures (e.g., facial and flexural psoriasis, eczema) with potent or very potent (WHO group III-IV) corticosteroids, vitamin D analogues or retinoids within 2 weeks prior to randomisation
- Topical treatment for other relevant skin disorders on the scalp (e.g. scalp psoriasis) with very potent (WHO group IV) corticosteroids, vitamin D analogues or retinoids within 2 weeks prior to randomisation
- Planned initiation of, or changes to concomitant medication that could affect psoriasis vulgaris (e.g., beta blockers, ACE inhibitors, anti-malaria drugs, lithium) within 2 weeks prior to randomisation
- Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the 4-week period prior to randomisation
- Subjects with current participation in any other interventional clinical trial
- Subjects with any of the following conditions present on the treatment area: eczematous skin, atopic dermatitis, clinical infection, ulcers and wounds
- Subjects with a history of serious allergy, allergic skin rash or sensitivity to any component of the investigational products or formulations being tested
- Subjects with positive hepatitis B, C or HIV
- Known or suspected severe renal insufficiency or severe hepatic disorders
- Known or suspected disorders of calcium metabolism associated with hypercalcaemia
- Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis
- Planned exposure to the sun during the study that may affect psoriasis vulgaris (i.e., normal lifestyle outdoor activities are permitted but deliberate exposure to sunlight or artificial ultraviolet light should be avoided)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:1个
|
Once daily application
|
有源比较器:2个
|
Twice daily application
|
安慰剂比较:3个
|
Twice daily application
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
The Percentage Change in PASI (Psoriasis Area Severity Index)
大体时间:From baseline (Day 0) to end of treatment (Day 28)
|
The following formula was used to calculate the PASI for each side of the body: Upper extremities: 0.2 (R + T+ S) E = X Trunk: 0.3 (R + T+ S) E = Y Lower extremities 0.4 (R + T+ S) E = Z where: R = score for redness T = score for thickness S = score for scaliness E = score for extent The sum of X + Y + Z gives the total PASI, which can range from 0 to 64.8. The PASI used in this study is modified to exclude assessment of the head, as study treatment was not used here. |
From baseline (Day 0) to end of treatment (Day 28)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Investigator's Global Assessment of Disease Severity
大体时间:At end of treatment (Day 28)
|
At all visits the (sub)investigator made a global assessment of the disease severity for psoriasis on the left and right side, respectively, of the body by use of the 6-point scale below. These assessments were to represent the average lesion severity on the left and right side, respectively. These assessments were to be based on the condition of the disease at the time of evaluation, and not in relation to the condition at a previous visit. Clear Almost clear Mild Moderate Severe Very severe |
At end of treatment (Day 28)
|
Participants With "Controlled Disease" According to the Investigator's Global Assessment of Disease Severity
大体时间:At end of treatment (Day 28)
|
For subjects with a baseline (Visit 1) severity of moderate or worse, "controlled disease" is defined as "clear" or "almost clear" according to the Investigator's global assessment of disease severity.
For subjects with a baseline (Visit 1) severity of mild, "controlled disease" is defined as "clear" according to the Investigator's global assessment of disease severity.
|
At end of treatment (Day 28)
|
Participant's Overall Assessment of Treatment Response
大体时间:At end of treatment (Day 28)
|
The participant assessed the treatment response by use of the 6-point scale below. Worse Unchanged Slight improvement Moderate improvement Marked improvement Almost clear Cleared |
At end of treatment (Day 28)
|
Participant's Assessment of Treatment Preference
大体时间:At end of treatment (Day 28)
|
At end of treatment (Day 28)
|
|
Participants With at Least 75% Reduction in PASI (PASI 75)
大体时间:From baseline (Day 0) to end of treatment (Day 28)
|
From baseline (Day 0) to end of treatment (Day 28)
|
|
Participants With at Least 50% Reduction in PASI (PASI 50)
大体时间:From baseline (Day 0) to end of treatment (day 28)
|
From baseline (Day 0) to end of treatment (day 28)
|
|
The Absolute Change in PASI (Psoriasis Area Severity Index)
大体时间:From baseline to end of treatment (Day 28)
|
The following formula was used to calculate the PASI for each side of the body: Upper extremities: 0.2 (R + T+ S) E = X Trunk: 0.3 (R + T+ S) E = Y Lower extremities 0.4 (R + T+ S) E = Z where: R = score for redness T = score for thickness S = score for scaliness E = score for extent The sum of X + Y + Z gives the total PASI, which can range from 0 to 64.8. The PASI used in this study is modified to exclude assessment of the head, as study treatment was not used here. |
From baseline to end of treatment (Day 28)
|
合作者和调查者
赞助
调查人员
- 首席研究员:Rodion Kunynetz, MD、Ultranova Skincare
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.